Plain-English translation of NCT07308548 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called HP515 to see if it can help treat non-alcoholic fatty liver disease — a condition where fat builds up in the liver. Researchers want to understand whether the medication works, how safe it is, and how your body processes it. You would take the medication or a placebo (a dummy pill) for 12 weeks while doctors monitor your health.
Non-alcoholic fatty liver disease affects millions of people and can lead to serious liver damage if left untreated. Currently, there are limited treatment options, so this trial is testing whether this new medication could offer patients a helpful way to reduce liver fat and prevent complications.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic several times over 4 months: first for screening tests (including liver imaging), then weekly or every few weeks for 12 weeks while taking the medication or placebo, with blood tests and scans to measure how your liver is responding. After the 12 weeks of treatment, you would have 4 more weeks of safety follow-up visits. Some blood samples would be taken on an empty stomach to help researchers understand how your body processes the medication.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China